Crispr Therapeutics AG ( (CRSP) ) has risen by 10.96%. Read on to learn why.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Crispr Therapeutics AG has seen a significant boost in its stock price, rising by 10.96% over the past week. This surge is largely driven by notable investment moves from Cathie Wood’s ARK Invest, which purchased over 102,000 shares of Crispr, valued at approximately $5.26 million. This move underscores Wood’s continued confidence in Crispr’s gene-editing platform, which has been a key focus in ARK’s biotech investments.
Further fueling the stock’s upward trajectory, Needham reaffirmed its Buy rating on Crispr Therapeutics, setting a price target of $81. This endorsement, along with Crispr’s promising update on their Phase 1/2 clinical study of CTX131, a CRISPR-Cas9-engineered treatment for blood cancers, has bolstered investor sentiment. The study’s progress highlights Crispr’s potential to provide innovative treatment solutions, enhancing its position in the competitive gene-editing and CAR T-cell therapy markets.
Analysts have responded positively to these developments, maintaining a ‘Buy’ rating on Crispr Therapeutics. The company’s strategic positioning and robust treatment pipeline are seen as key drivers of investor interest. As Crispr continues to advance its clinical studies, its stock remains a focal point for investors seeking opportunities in the healthcare sector, promising further growth potential in the genetic editing landscape.